drugset / Trial / NCT04553666
Reducing Frailty for Older Cancer Survivors Using Supplements
RandomizedParallel-groupOpen-labelSupportive care
Summary
The purpose of the study is to examine the feasibility and safety of twelve weeks oral supplementation of Epigallocatechin-3-gallate (EGCG) in older survivors of cancer
Timeline
- Start
- 2021-04-28
- Primary completion
- 2023-08-31
- Completion
- 2023-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vitamin C | Other / unclassified | 250 mg | Oral |
| Subject | epigallocatechin-3-gallate | Unknown | 800 mg | Oral |
Indications
No indication recorded.